Dihexa: The "Neurogenic" Peptide 10 Million Times Stronger than BDNF
Developed to treat Alzheimer’s, Dihexa is shown to build new neural connections at a rate that dwarfs standard nootropics.
Table of Contents
Key Research Insights
- Dihexa(PNB -0408) is an oligopeptide drug variant derived from Angiotensin IV, developed by researchers at Washington State University.
- It is characterized by its exceptionally high biological activity in promoting synaptogenesis(formation of new neural connections).
- Research indicates it is up to seven orders of magnitude more potent than Brain - Derived Neurotrophic Factor(BDNF) in stimulating dendritic arborization.
- Principal research applications focus on neurodegenerative conditions like Alzheimer's disease and cognitive impairment.
Mechanism of Action
Dihexa functions as a hepatocyte growth factor(HGF) mimetic.It binds to HGF and potentiates its interaction with the c - Met receptor.
The c - Met Pathway
Activation of the c - Met receptor initiates a cascade of signaling pathways(PI3K / Akt and MAPK / ERK) crucial for:
- ** Synaptogenesis:** The formation of new synapses between neurons.
- ** Neuroprotection:** Preventing neuronal death from excitotoxicity or oxidative stress.
- ** Cognitive Enhancement:** Strengthening neural circuits involved in memory and learning[1].
Research Findings
Alzheimer's Disease Models
In animal models of Alzheimer's type neurodegeneration (scopolamine-induced amnesia), Dihexa treatment demonstrated remarkable reversal of cognitive deficits. It restored spatial learning and memory capabilities to levels comparable with healthy controls[1].
Potency Comparison
In comparative assays, Dihexa was evaluated against BDNF for its ability to induce dendritic spine formation.While BDNF is a powerful endogenous factor, Dihexa achieved similar synaptogenic effects at significantly lower concentrations(picomolar range), highlighting its potential as a clinically viable therapeutic.
Safety and Bioavailability
Unlike many peptides, Dihexa is orally bioavailable and can cross the blood - brain barrier effectively.Preclinical toxicology studies have suggested a favorable safety margin, though long - term human data remains limited.
References
[1] McCoy AT, et al. "Dihexa: a potent hepatocyte growth factor mimetic." * Journal of Pharmacology and Experimental Therapeutics *. 2013. [2] "Angiotensin IV analogs as cognitive enhancers." * Peptides *. [3] "HGF/c-Met signaling in the nervous system." * Trends in Neurosciences *.